reviewTop 1% cited
HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention
Oncogene · 2007 · Vol. 26(37) · pp. 5310–5318
X-J Yang✉(McGill University)Edward Seto✉(Moffitt Cancer Center)
Histone Deacetylase Inhibitors ResearchProtein Degradation and InhibitorsEpigenetics and DNA MethylationAcetylationBiologyHistoneLysineHistone-modifying enzymesHistone AcetyltransferasesGeneticsCell biologyBiochemistryGene
MeSH terms
AcetylationEnzyme InhibitorsHistone DeacetylasesHumansLysineProtein Processing, Post-TranslationalHistone AcetyltransferasesHistone Deacetylase Inhibitors
Citations
1,023
FWCI
17.42
field-weighted impact
References
142
Percentile
100%
vs. same field & year
Citations per year
Cited by
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
British Journal of Clinical Pharmacology · 2021 · 401 citations
References
CBP/p300 in cell growth, transformation, and development
Genes & Development · 2000 · 1,757 citations
Histone deacetylases and cancer
Oncogene · 2007 · 1,039 citations
Substrate and Functional Diversity of Lysine Acetylation Revealed by a Proteomics Survey
Molecular Cell · 2006 · 1,476 citations
Acetylation: a regulatory modification to rival phosphorylation?
The EMBO Journal · 2000 · 1,150 citations
Histone deacetylase inhibitors: molecular mechanisms of action
Oncogene · 2007 · 1,533 citations
Histone deacetylases, transcriptional control, and cancer
Journal of Cellular Physiology · 2000 · 622 citations
Chromatin Modifications and Their Function
Cell · 2007 · 10,677 citations
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Nature reviews. Cancer · 2006 · 2,190 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.